AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations

Cancer Discovery

Volumn 7, Issue 5, 2017, Pages 478-493

  Yen, Katharine ^a   Travins, Jeremy ^a   Wang, Fang ^a   David, Muriel D ^b,c,d   Artin, Erin ^a   Straley, Kimberly ^a,i   Padyana, Anil ^a   Gross, Stefan ^a   Delabarre, Byron ^a,j   Tobin, Erica ^a   Chen, Yue ^a   Nagaraja, Raj ^a   Choe, Sung ^a   Jin, Lei ^a   Konteatis, Zenon ^a   Cianchetta, Giovanni ^a   Saunders, Jeffrey O ^a,k   Salituro, Francesco G ^a,l   Quivoron, Cyril ^b,c,d   Opolon, Paule ^c   Bawa, Olivia ^c   Saada, Véronique ^b,c,d   Paci, Angelo ^c   Broutin, Sophie ^c   Bernard, Olivier A ^b,c,d   De Botton, Stéphane ^b,c,d   Marteyn, Benoît S ^c,e   Pilichowska, Monika ^f   Xu, Yingxia ^g   Fang, Cheng ^g   Jiang, Fan ^h   Wei, Wentao ^h   Jin, Shengfang ^a   Silverman, Lee ^a   Liu, Wei ^a   Yang, Hua ^a   Dang, Lenny ^a   Dorsch, Marion ^a   Penard Lacronique, Virginie ^b,c,d   Biller, Scott A ^a   Michael Su, Shin San ^a   more..

^a AGIOS PHARMACEUTICALS   (United States)

^b Universite Paris Sud   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d Equipe Labellisée Ligue Nationale Contre le Cancer   (France)

^e INSTITUT PASTEUR   (France)

^f TUFTS MEDICAL CENTER   (United States)

^g ShangPharma ^*  (China)

^h Viva Biotech Ltd   (China)

ⁱ VERTEX PHARMACEUTICALS   (United States)

^j The Consulting Biochemist   (United States)

^k Resilience Therapeutics   (United States)

^l Sage Therapeutics Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYGLUTARIC ACID; CD11 ANTIGEN; CD11B ANTIGEN; CD14 ANTIGEN; CD15 ANTIGEN; CD24 ANTIGEN; CYTARABINE; ENASIDENIB; ERYTHROPOIETIN; HEMOGLOBIN A; ISOCITRATE DEHYDROGENASE 2; KRUPPEL LIKE FACTOR; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR RUNX3; AG-221; AMINOPYRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN; TRIAZINE DERIVATIVE;

ACUTE MYELOID LEUKEMIA; ADULT; AFFINITY CHROMATOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION ASSAY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DNA METHYLATION; DRUG SYNTHESIS; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC50; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; LOW DRUG DOSE; MOUSE; NONHUMAN; PHAGOCYTOSIS; PHARMACODYNAMICS; POLYMERASE CHAIN REACTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN STRUCTURE; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; SIZE EXCLUSION CHROMATOGRAPHY; SURVIVAL; X RAY CRYSTALLOGRAPHY; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG SCREENING; GENETICS; MUTATION; TUMOR CELL LINE;

AMINOPYRIDINES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HUMANS; ISOCITRATE DEHYDROGENASE; LEUKEMIA, MYELOID, ACUTE; MICE; MUTATION; TRIAZINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85018387546     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-16-1034     Document Type: Article

References (50)

1. Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab 2016;23:27–47.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144:646–74.
3. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807–12.
4. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360: 765–73.
5. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009;361:1058–66.
6. Kosmider O, Gelsi-Boyer V, Slama L, Dreyfus F, Beyne-Rauzy O, Quesnel B, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia 2010;24:1094–6.
7. Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 2012;17:72–9.
8. Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 2011;224:334–43.
9. Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 2010;207:339–44.
10. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;462:739–44.
11. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010;17:225–34.
12. Chowdhury R, Yeoh KK, Tian YM, Hillringhaus L, Bagg EA, Rose NR, et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep 2011;12:463–9.
13. Koivunen P, Lee S, Duncan CG, Lopez G, Lu G, Ramkissoon S, et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 2012;483:484–8.
14. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutaratedependent dioxygenases. Cancer Cell 2011;19:17–30.
15. Losman JA, Looper RE, Koivunen P, Lee S, Schneider RK, McMahon C, et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 2013;339:1621–5.
16. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010;18:553–67.
17. Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 2013;340:622–6.
18. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012;483:479–83.
19. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012;483:474–8.
20. Saha SK, Parachoniak CA, Ghanta KS, Fitamant J, Ross KN, Najem MS, et al. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature 2014;513:110–4.
21. Lu C, Venneti S, Akalin A, Fang F, Ward PS, Dematteo RG, et al. Induction of sarcomas by mutant IDH2. Genes Dev 2013;27:1986–98.
22. Okoye-Okafor UC, Bartholdy B, Cartier J, Gao EN, Pietrak B, Rendina AR, et al. New IDH1 mutant inhibitors for treatment of acute myeloid leukemia. Nat Chem Biol 2015;11:878–86.
23. Chen C, Liu Y, Lu C, Cross JR, Morris 4th JP, Shroff AS, et al. Cancerassociated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes Dev 2013;27:1974–85.
24. Kats LM, Reschke M, Taulli R, Pozdnyakova O, Burgess K, Bhargava P, et al. Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. Cell Stem Cell 2014;14:329–41.
25. Sasaki M, Knobbe CB, Munger JC, Lind EF, Brenner D, Brustle A, et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 2012;488:656–9.
26. Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014;506:328–33.
27. Corces-Zimmerman MR, Hong WJ, Weissman IL, Medeiros BC, Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci U S A 2014;111:2548–53.
28. Sykes SM, Kokkaliaris KD, Milsom MD, Levine RL, Majeti R. Clonal evolution of preleukemic hematopoietic stem cells in acute myeloid leukemia. Exp Hematol 2015;43:989–92.
29. Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrozek K, Margeson D, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 2010;28:2348–55.
30. Green CL, Evans CM, Zhao L, Hills RK, Burnett AK, Linch DC, et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood 2011;118:409–12.
31. Losman JA, Kaelin WG Jr. What a difference a hydroxyl makes: Mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev 2013;27: 836–52.
32. Pietrak B, Zhao H, Qi H, Quinn C, Gao E, Boyer JG, et al. A tale of two subunits: How the neomorphic R132H IDH1 mutation enhances production of αHG. Biochemistry 2011;50:4804–12.
33. Yang B, Zhong C, Peng Y, Lai Z, Ding J. Molecular mechanisms of “off-on switch” of activities of human IDH1 by tumor-associated mutation R132H. Cell Res 2010;20:1188–200.
34. Fathi AT, Sadrzadeh H, Borger DR, Ballen KK, Amrein PC, Attar EC, et al. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood 2012;120:4649–52.
35. Cowland JB, Borregaard N. Granulopoiesis and granules of human neutrophils. Immunol Rev 2016;273:11–28.
36. Döhner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453–74.
37. DiNardo CD, Ravandi F, Agresta S, Konopleva M, Takahashi K, Kadia T, et al. Characteristics, clinical outcome and prognostic significance of IDH mutations in AML. Am J Hematol 2015;90:732–6.
38. DiNardo CD, Jabbour E, Ravandi F, Takahashi K, Daver N, Routbort M, et al. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression. Leukemia 2015;30:980–4.
39. Kernytsky A, Wang F, Hansen E, Schalm S, Straley K, Gliser C, et al. IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition. Blood 2015;125:296–303.
40. Wang ZY, Chen Z. Acute promyelocytic leukemia: From highly fatal to highly curable. Blood 2008;111:2505–15.
41. Stein EM, DiNardo C, Altman JK, Collins R, DeAngelo DJ, Kantarjian HM, et al. Safety and efficacy of AG-221, a potent inhibitor of mutant IDH2 that promotes differentiation of myeloid cells in patients with advanced hematologic malignancies: Results of a phase 1/2 trial. Blood 2015;126:323.
42. Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 1997;276:307–26.
43. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. J Appl Crystallogr 2007;40:658–74.
44. Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr D Biol Crystallogr 2010;66:486–501.
45. Murshudov GN, Skubak P, Lebedev AA, Pannu NS, Steiner RA, Nicholls RA, et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr D Biol Crystallogr 2011;D67:355–67.
46. Boissel N, Nibourel O, Renneville A, Gardin C, Reman O, Contentin N, et al. Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: A study by the Acute Leukemia French Association group. J Clin Oncol 2010;28:3717–23.
47. Merlevede J, Droin N, Qin T, Meldi K, Yoshida K, Morabito M, et al. Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. Nat Commun 2016;7:10767.
48. Poinsignon V, Mercier L, Nakabayashi K, David MD, Lalli A, Penard- Lacronique V, et al. Quantitation of isocitrate dehydrogenase (IDH)- induced D and L enantiomers of 2-hydroxyglutaric acid in biological fluids by a fully validated liquid tandem mass spectrometry method, suitable for clinical applications. J Chromatogr B Analyt Technol Biomed Life Sci 2016;1022:290–7.
49. Monceaux V, Chiche-Lapierre C, Chaput C, Witko-Sarsat V, Prevost MC, Taylor CT, et al. Anoxia and glucose supplementation preserve neutrophil viability and function. Blood 2016;128:993–1002.
50. Hu S, Niu H, Inaba H, Orwick S, Rose C, Panetta JC, et al. Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. J Natl Cancer Inst 2011;103:893–905.